Adipose Stem Cell Heart Attack Trial Data Published in Journal of the American College of Cardiology; Cytori’s APOLLO Trial Demonstrated Safety & Feasibility and Improvements in Cardiac Function
Cytori Therapeutics announced today the publication of previously reported six-month outcomes from APOLLO, the Company’s European clinical trial evaluating adipose-derived stem and regenerative cells (ADRCs) in patients with acute myocardial infarction (heart attack or AMI), as Research Correspondence in the Journal of the American College of Cardiology. The APOLLO trial was a 14-patient, prospective, randomized, double-blind, placebo-controlled, feasibility trial (Phase I/IIA) evaluating autologous ADRCs extracted with the Company’s proprietary Celution® System for
Stem cells could be responsible for some forms of aggressive thyroid tumors (ATC, anaplastic thyroid carcinoma). The discovery was made by a young group of biotechnologists, biologists, and doctors from the Endocrinology department of the General Hospital of the University of Palermo. In the study, published in Plos One, the researchers described a subset of tumor stem cells that were able to proliferate continuously and may be responsible for uncontrolled tumor growth. These cells are resistant to chemotherapy and explain why ATC is so highly fatal in such a short period of time. The
A team of researchers from UCL has won a £500,000 grant to develop a synthetic artery that mimics a natural artery – and could revolutionise the treatment of coronary heart disease.
Professor Alexander Seifalian (UCL Surgery and Interventional Science) and Professor George Hamilton (UCL Surgery and Interventional Science & Royal Free Hospital) and their team will use the Wellcome Trust grant to take their work from the laboratory to a pre-clinical trial.
The team has been developing a new nanomaterial with mechanical properties similar to that of human arteries.
The nanomaterial’s inner surface has been modified to attract stem cells from blood
Image via Wikipedia
Misleading advertisements by Swedish company Labo promising hair growth and to remove wrinkles have been pulled. The jury of the self-regulating body for the advertising industry (IAP) ordered the advertisements, which were found in two important Italian newspapers, to be stopped since they were “in violation of article 2 of the self-regulatory code for advertisements”.
According to the group’s conclusions (ruling number 13/09), the statements made in the message, as noted by the IAP Surveillance Committee, “did not overstate, they were misleading”.
This is due to the fact that “they were characterized by a technical and scientific language
Hans Keirstead, a researcher at University of California, Irvine, is set to begin a small human trial of his embryonic stem cell treatment on patients with spinal cord injuries. The treatment is designed for patients within 14 days of suffering spinal cord injuries. In rat trials, paralyzed rats were injected with a stem cell formula. The paralyzed rats were able to walk six weeks later.